Baidu
map

Mol Cancer:研究发现卵巢癌新的治疗靶点

2017-09-04 MedSci MedSci原创

越来愈多的研究表明lncRNAs在肿瘤细胞的增殖、分化和凋亡中发挥着重要的作用。研究人员使用实时荧光定量PCR(qRT-PCR)研究了上皮性卵巢癌(EOC)和正常卵巢组织中lncRNA ABHD11-AS1的表达。通过小干扰RNA(siRNA)下调ABHD11-AS1或质粒转染过表达ABHD11-AS1,检测卵巢癌细胞表型及相关分子的表达。结果显示,在卵巢癌组织中的lncRNA ABHD11-AS

越来越多的研究表明lncRNAs在肿瘤细胞的增殖、分化和凋亡中发挥着重要的作用。

研究人员使用实时荧光定量PCR(qRT-PCR)研究了上皮性卵巢癌(EOC)和正常卵巢组织中lncRNA ABHD11-AS1的表达。通过小干扰RNA(siRNA)下调ABHD11-AS1或质粒转染过表达ABHD11-AS1,检测卵巢癌细胞表型及相关分子的表达。

结果显示,在卵巢癌组织中的lncRNA ABHD11-AS1的表达明显高于正常卵巢组织。且其表达水平与肿瘤分期(I/II vs. III/IV)呈正相关,高分化组的表达水平较中分化组低。卵巢癌细胞株A2780和OVCAR3中ABHD11-AS1过表达可促进卵巢癌细胞的增殖、侵袭和迁移,并可抑制细胞的凋亡。沉默ABHD11-AS1则会有相反的效果。

裸鼠皮下注射肿瘤细胞显示ABHD11-AS1能明显促进肿瘤生长。另外,在裸鼠体内腹腔注射肿瘤细胞可提高肿瘤的转移能力。进一步探究,ABHD11-AS1过度表达可上调RhoC及其下游分子p70S6K、MMP2和Bcl-xl表达。沉默ABHD11-AS1则有相反的效果。RNA pull-down分析显示,ABHD11-AS1可以直接与RhoC结合。沉默RhoC可抑制lncRNA ABHD11-AS1的促癌作用。因此,RhoC似乎是lncRNA ABHD11-AS1的主要作用目标。

总之,该研究首次表明了RhoC在 lncRNA ABHD11-AS1促肿瘤中的作用,该研究发现揭示了卵巢癌治疗的新靶点。

原始出处:

Dan-Dan Wu, Xi Chen, et al., Role of the lncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC. Mol Cancer. 2017; 16: 138. Published online 2017 Aug 17. doi: 10.1186/s12943-017-0709-5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1753278, encodeId=000c1e5327870, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue Nov 14 15:07:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895342, encodeId=cd8018953424e, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Jul 09 04:07:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240420, encodeId=929e24042064, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Sep 04 17:11:13 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240400, encodeId=1369240400d8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 04 16:14:45 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1753278, encodeId=000c1e5327870, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue Nov 14 15:07:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895342, encodeId=cd8018953424e, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Jul 09 04:07:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240420, encodeId=929e24042064, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Sep 04 17:11:13 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240400, encodeId=1369240400d8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 04 16:14:45 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1753278, encodeId=000c1e5327870, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue Nov 14 15:07:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895342, encodeId=cd8018953424e, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Jul 09 04:07:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240420, encodeId=929e24042064, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Sep 04 17:11:13 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240400, encodeId=1369240400d8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 04 16:14:45 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2017-09-04 天涯183

    非常好的文章.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1753278, encodeId=000c1e5327870, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Tue Nov 14 15:07:00 CST 2017, time=2017-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895342, encodeId=cd8018953424e, content=<a href='/topic/show?id=18ae64e21d3' target=_blank style='color:#2F92EE;'>#治疗靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64721, encryptionId=18ae64e21d3, topicName=治疗靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Mon Jul 09 04:07:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240420, encodeId=929e24042064, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Mon Sep 04 17:11:13 CST 2017, time=2017-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=240400, encodeId=1369240400d8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Mon Sep 04 16:14:45 CST 2017, time=2017-09-04, status=1, ipAttribution=)]
    2017-09-04 luominglian113

    学习了.谢谢分享

    0

相关资讯

Anal Cell Pathol:研究阐明 MIR4697HG在卵巢癌生长及转移中的作用

卵巢癌是世界上最常见的三大妇科恶性肿瘤之一。由于治疗策略的限制,这种恶性肿瘤患者的预后仍然很差。本研究中,研究人员探究了了一种长链非编码RNA (MIR4697HG)在卵巢癌细胞生长与转移中的作用。结果表明,癌组织中MIR4697HG的转录水平较癌旁组织增加了一倍。卵巢癌细胞系中MIR4697HG的表达不同,OVCAR3 和 SKOV3细胞中表达水平最高。通过特定的shRNA敲除MIR4697HG

Int J Cancer:痛经会导致卵巢癌风险增加

痛经是一种常见的妇科疾病,指行经前后或月经期出现下腹部疼痛、坠胀,伴有腰酸或其他不适,症状严重影响生活质量者。痛经分为原发性痛经和继发性两类,原发性痛经指生殖器官无器质性病变的痛经,占痛经90%以上;继发性痛经指由盆腔器质性疾病引起的痛经。在既往的研究中,部分研究的结果表明它与女性患卵巢癌的风险相关,但并非所有的研究都如此。此外,由于缺乏动力,痛经和卵巢癌的不同组织学亚型之间的潜在变化还没有得到充

Int J Cancer:抗抑郁药或能降低卵巢上皮癌的风险

卵巢上皮癌是常见的妇科恶性肿瘤,占卵巢肿瘤的;50%-70%.由于EOC早期(I、II期)缺乏典型临床表观。76%的病人在发现时已有腹腔内种植,肝实质和/或胸腔、颅内转移(III、IV期)这是导致较高病死率的主要原因。 抗抑郁药治疗在女性中被广泛使用,主要治疗抑郁症和焦虑症,但目前很少有研究探讨抗抑郁药对妇科癌症风险的影响。

Oncotarget:老标记新功能,血清CA125浓度预测卵巢癌转移

卵巢恶性肿瘤是女性生殖器官常见的恶性肿瘤之一,对妇女生命造成严重威胁。由于卵巢的胚胎发育、组织解剖及内分泌功能较复杂,早期症状不典型,术前鉴别卵巢肿瘤的组织类型及良恶性相当困难。

SCI REP:卵巢癌患者辅助化疗起始时间与生存率之间的关系!

总之,辅助化疗起始时间延长与卵巢癌患者总体生存率降低有关,尤其是在晚期卵巢癌患者。

J CLIN ONCOL:延长无铂间期能否为铂类部分敏感的卵巢癌患者带来生存获益?

对于无铂间期(PFI)6至12个月的卵巢癌复发患者,临床上通过引入非铂药物来延长PFI并增加患者对铂类药物的敏感性。但是由Sandro Pignata教授主导于2017年8月21日发表在JOURNAL OF CLINICAL ONCOLOGY上的MITO-8研究则发现,这种治疗策略并不使对铂类药物部分敏感的卵巢癌患者取得生存获益。

Baidu
map
Baidu
map
Baidu
map